

# Ge Bai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5530309/publications.pdf>

Version: 2024-02-01

52  
papers

940  
citations

430874

18  
h-index

501196

28  
g-index

53  
all docs

53  
docs citations

53  
times ranked

848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extreme Markup: The Fifty US Hospitals With The Highest Charge-To-Cost Ratios. Health Affairs, 2015, 34, 922-928.	5.2	140
2	A More Detailed Understanding Of Factors Associated With Hospital Profitability. Health Affairs, 2016, 35, 889-897.	5.2	91
3	Cost-effectiveness analysis comparing lumen-apposing metal stents with plastic stents in the management of pancreatic walled-off necrosis. Gastrointestinal Endoscopy, 2018, 88, 267-276.e1.	1.0	70
4	US Hospitals Are Still Using Chargemaster Markups To Maximize Revenues. Health Affairs, 2016, 35, 1658-1664.	5.2	67
5	Analysis Suggests Government And Nonprofit Hospitals' Charity Care Is Not Aligned With Their Favorable Tax Treatment. Health Affairs, 2021, 40, 629-636.	5.2	38
6	Variation in the Ratio of Physician Charges to Medicare Payments by Specialty and Region. JAMA - Journal of the American Medical Association, 2017, 317, 315.	7.4	36
7	Plastic stents are more cost-effective than lumen-apposing metal stents in management of pancreatic pseudocysts. Endoscopy International Open, 2018, 06, E780-E788.	1.8	33
8	Varying Trends In The Financial Viability Of US Rural Hospitals, 2011-2017. Health Affairs, 2020, 39, 942-948.	5.2	32
9	Variation in Emergency Department vs Internal Medicine Excess Charges in the United States. JAMA Internal Medicine, 2017, 177, 1139.	5.1	31
10	Hospital Cost Structure and the Implications on Cost Management During COVID-19. Journal of General Internal Medicine, 2020, 35, 2807-2809.	2.6	29
11	Factors Associated with Compliance to the Hospital Price Transparency Final Rule: a National Landscape Study. Journal of General Internal Medicine, 2022, 37, 3577-3584.	2.6	28
12	Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs. JAMA - Journal of the American Medical Association, 2019, 322, 422.	7.4	27
13	PPE Supply Chain Needs Data Transparency and Stress Testing. Journal of General Internal Medicine, 2020, 35, 2748-2749.	2.6	26
14	Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing. Annals of Internal Medicine, 2018, 168, 436.	3.9	24
15	Commercial Negotiated Prices for CMS-specified Shoppable Radiology Services in U.S. Hospitals. Radiology, 2022, 302, 622-624.	7.3	24
16	Comparison of US Hospital Cash Prices and Commercial Negotiated Prices for 70 Services. JAMA Network Open, 2021, 4, e2140526.	5.9	24
17	Market Power: Price Variation Among Commercial Insurers For Hospital Services. Health Affairs, 2018, 37, 1615-1622.	5.2	20
18	Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim. Value in Health, 2020, 23, 481-486.	0.3	19

#	ARTICLE	IF	CITATIONS
19	Comparative Approaches to Drug Pricing. Annual Review of Public Health, 2020, 41, 499-512.	17.4	17
20	Charity Care Provision by US Nonprofit Hospitals. JAMA Internal Medicine, 2020, 180, 606.	5.1	17
21	COVID-19 and Hospital Financial Viability in the US. JAMA Health Forum, 2022, 3, e221018.	2.2	17
22	Air Ambulances With Sky-High Charges. Health Affairs, 2019, 38, 1195-1200.	5.2	16
23	Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context. American Journal of Public Health, 2019, 109, 559-561.	2.7	13
24	Commercial negotiated prices for CMS-specified shoppable surgery services in U.S. hospitals. International Journal of Surgery, 2021, 95, 106107.	2.7	10
25	<i>The Impact of Price Transparency for Surgical Services</i>. American Surgeon, 2018, 84, 604-608.	0.8	9
26	Decreasing Medicare Utilization, Reimbursement, and Reimbursement-to-Charge Ratio of Reconstructive Plastic Surgery Procedures: 2010 to 2019. Annals of Plastic Surgery, 2022, 88, 549-554.	0.9	9
27	Evaluation of Unreimbursed Medicaid Costs Among Nonprofit and For-Profit US Hospitals. JAMA Network Open, 2022, 5, e2148232.	5.9	9
28	Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical Advertising. JAMA Internal Medicine, 2019, 179, 435.	5.1	7
29	Nurse practitioners and physician assistants in emergency medical services who billed independently, 2012â€“2016. American Journal of Emergency Medicine, 2019, 37, 928-932.	1.6	7
30	Increasing frequency and share of dermatologic procedures billed by nonphysician clinicians from 2012 to 2016. Journal of the American Academy of Dermatology, 2018, 79, 1159-1161.	1.2	6
31	Lobbying Expenditures of the Health Sector During the COVID-19 Pandemic. Journal of General Internal Medicine, 2020, 35, 3133-3136.	2.6	6
32	NIH funding of COVID-19 research in 2020: a cross-sectional study. BMJ Open, 2022, 12, e059041.	1.9	5
33	Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States. Journal of General Internal Medicine, 2023, 38, 3640-3643.	2.6	4
34	Trends in Hospital Lawsuits Filed Against Patients for Unpaid Bills Following Published Research About This Activity. JAMA Network Open, 2021, 4, e2121926.	5.9	4
35	Naming Convention, Interchangeability, and Patient Interest in Biosimilars. Diabetes Spectrum, 2020, 33, 273-279.	1.0	4
36	Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program. JAMA Network Open, 2021, 4, e210483.	5.9	3

#	ARTICLE	IF	CITATIONS
37	Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. American Journal of Health-System Pharmacy, 2021, 78, 216-221.	1.0	3
38	Investment Income of US Nonprofit Hospitals in 2017. Journal of General Internal Medicine, 2020, 35, 2818-2820.	2.6	2
39	Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs. Journal of General Internal Medicine, 2021, 36, 555-556.	2.6	2
40	Labor Market Concentration and Worker Contributions to Health Insurance Premiums. Medical Care Research and Review, 2021, , 107755872110129.	2.1	2
41	Comparison of Trends in Nonprofit Hospitals' Charity Care Eligibility Policies Between Medicaid Expansion States and Medicaid Nonexpansion States. Medical Care Research and Review, 2022, 79, 458-468.	2.1	2
42	Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019. JAMA Health Forum, 2022, 3, e220888.	2.2	2
43	Bipartisan Federal Legislation to Address Insulin Access and Affordability. Diabetes Spectrum, 2021, 34, ds210008.	1.0	1
44	Hospital Inpatient Charges of COVID-19 Diagnostic Tests Ranged from \$10 to \$1390. Population Health Management, 2021, 24, 433-435.	1.7	1
45	Association Between Waste-Free Formularies and Prescription Drug Spending Among Self-insured Employers. JAMA Network Open, 2021, 4, e2131486.	5.9	1
46	The Identification of Outlier Medical Specialties from Examining the Association Between the Change in Charges and the Change in Medicare Payments from 2010 to 2019. Journal of General Internal Medicine, 2022, 37, 3220-3223.	2.6	1
47	Effectiveness of Email Warning on Reducing Hospital Employees' Unauthorized Access to Protected Health Information. JAMA Network Open, 2022, 5, e227247.	5.9	1
48	Physician Charges and Medicare Payments. JAMA - Journal of the American Medical Association, 2017, 317, 1802.	7.4	0
49	Services Provided By Internal Medicine Physicians Compared With Emergency Physicians: Flawed Data. JAMA Internal Medicine, 2018, 178, 297.	5.1	0
50	The Commissions Paid to Brokers for Fully Insured Health Insurance Plans. Medical Care Research and Review, 2020, , 107755872098056.	2.1	0
51	A Nonprofit Public Utility Approach to Enhance Next-Generation Vaccine Manufacturing Capacity. Population Health Management, 2021, 24, 546-547.	1.7	0
52	Financial Implications of COVID-19 Polymerase Chain Reaction Tests on Independent Laboratories. Journal of General Internal Medicine, 0, , .	2.6	0